Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 314
Filter
1.
J Med Microbiol ; 71(6)2022 Jun.
Article in English | MEDLINE | ID: mdl-35687657

ABSTRACT

Candida auris is a recently emerged multidrug-resistant fungal pathogen that causes life-threatening infections to the human population worldwide. Recent rampant outbreaks of C. auris in coronavirus disease 2019 (COVID-19) patients, together with outbreaks in over 45 countries, highlight its threat to patients and healthcare economies. Unlike other pathogenic Candida species, C. auris is capable of surviving in abiotic surfaces of healthcare facilities for prolonged periods, leading to increased risk of transmission within nosocomial settings. C. auris is resistant to multiple classes of antifungal agents, forms dry biofilms and transmits independently to regional epicentres, making its eradication from nosocomial environment arduous. The lack of strategies for environmental decontamination of C. auris from nosocomial settings is evident from the generic guidance and recommendations provided by leading global healthcare bodies. Therefore, this minireview discusses the current guidelines for environmental decontamination of C. auris and compounds and strategies currently under investigation for potential future use. While established guidelines recommend the use of products mainly consisting of sodium hypochlorite and hydrogen peroxide, initial works have been reported on the promising anti-C. auris properties of various other compounds and some biocompatible alternatives. Further validation of these approaches, coupled up with environmentally friendly decontamination protocols, are warranted to achieve superior elimination of C. auris from healthcare settings.


Subject(s)
COVID-19 , Cross Infection , Antifungal Agents/pharmacology , COVID-19/prevention & control , Candida , Candida auris , Cross Infection/prevention & control , Decontamination , Humans
2.
Sci Rep ; 10(1): 7769, 2020 05 08.
Article in English | MEDLINE | ID: mdl-32385378

ABSTRACT

Microorganisms employ quorum sensing (QS) mechanisms to communicate with each other within microbial ecosystems. Emerging evidence suggests that intraspecies and interspecies QS plays an important role in antimicrobial resistance in microbial communities. However, the relationship between interkingdom QS and antimicrobial resistance is largely unknown. Here, we demonstrate that interkingdom QS interactions between a bacterium, Pseudomonas aeruginosa and a yeast, Candida albicans, induce the resistance of the latter to a widely used antifungal fluconazole. Phenotypic, transcriptomic, and proteomic analyses reveal that P. aeruginosa's main QS molecule, N-(3-Oxododecanoyl)-L-homoserine lactone, induces candidal resistance to fluconazole by reversing the antifungal's effect on the ergosterol biosynthesis pathway. Accessory resistance mechanisms including upregulation of C. albicans drug-efflux, regulation of oxidative stress response, and maintenance of cell membrane integrity, further confirm this phenomenon. These findings demonstrate that P. aeruginosa QS molecules may confer protection to neighboring yeasts against azoles, in turn strengthening their co-existence in hostile polymicrobial infection sites.


Subject(s)
Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/physiology , Drug Resistance, Fungal , Fluconazole/pharmacology , Pseudomonas aeruginosa/physiology , Quorum Sensing , Biosynthetic Pathways , Ergosterol/biosynthesis , Gene Expression Regulation, Fungal/drug effects , Microbial Interactions
3.
Int J Pharm ; 578: 119096, 2020 Mar 30.
Article in English | MEDLINE | ID: mdl-32006626

ABSTRACT

In contrast to the plethora of antibacterial agents, only a handful of antifungals are currently available to treat Candida albicans biofilm-associated infections. Additional novel antibiofilm strategies to eliminate C. albicans biofilm infections are needed. This study aims to improve the efficacy of a widely used azole, fluconazole by co-delivering it with a Pseudomonas aeruginosa quorum sensing molecule (QSM), N-3-oxo-dodecanoyl-L-homoserine lactone (C12AHL) in a liposomal formulation. C12AHL is known to inhibit C. albicans' morphological transition and biofilm formation. Four different formulations of liposomes with fluconazole (L-F), with C12AHL (L-H), with fluconazole and C12AHL (L-HF), and a drug-free control (L-C) were prepared using a thin-film hydration followed by extrusion method, and characterised. The effect of liposomes on colonising (90 min-24 h) and preformed (24 h) C. albicans biofilms were assessed using a standard biofilm assay. Biofilm viability (XTT reduction assay), biomass (Safranin-O staining) and architecture (confocal laser scanning microscopy, CLSM) were determined. Similar efficiencies of fluconazole entrapment were noticed in L-HF and L-F (11.74% vs 10.2%), however, L-HF released greater quantities of fluconazole compared to L-F during 24 h (4.27% vs 0.97%, P < 0.05). The entrapment and release of C12AHL was similar for L-H and L-HF liposomes (33.3% vs 33% and 88.9% vs 92.3% respectively). L-HF treated colonising, and preformed biofilms exhibited >80%, and 60% reduction in their respective viabilities at a fluconazole concentration as low as 5.5 µg/mL compared to 12% and 36%, respective reductions observed in L-F treated biofilms (P < 0.05). CLSM confirmed biofilm disruption, lack of hyphae, and reduction in biomass when treated with L-HF compared to other liposomal preparations. Liposomal co-delivery of C12AHL and fluconazole appears to suppress C. albicans biofilms through efficacious disruption of the biofilm, killing of constituent yeasts, and diminishing their virulence at a significantly lower antifungal dose. Therefore, liposomal co-formulation of C12AHL and fluconazole appears to be a promising approach to improve the efficacy of this common triazole against biofilm-mediated candidal infections.


Subject(s)
4-Butyrolactone/analogs & derivatives , Antifungal Agents/administration & dosage , Candida albicans/drug effects , Drug Delivery Systems , Fluconazole/administration & dosage , Homoserine/analogs & derivatives , Pseudomonas aeruginosa/physiology , Quorum Sensing , 4-Butyrolactone/administration & dosage , 4-Butyrolactone/chemistry , Antifungal Agents/chemistry , Biofilms/drug effects , Candida albicans/physiology , Drug Liberation , Fluconazole/chemistry , Homoserine/administration & dosage , Homoserine/chemistry , Liposomes
4.
Oral Dis ; 24(4): 518-526, 2018 May.
Article in English | MEDLINE | ID: mdl-28513096

ABSTRACT

Pathobiology of dental caries is complex. Data from recent molecular microbiologic studies have further redefined the role of the oral microbiome in the etiology of dental caries. This new information challenges the conventional view on the hegemony of classic cariogenic prokaryotes such as Streptococcus mutans in caries etiology, and raises the intriguing possibility of the participation of the eukaryotic oral fungal pathogen Candida in the caries process. The virulence attributes of Candida species such as their acidogenicity and aciduric nature, the ability to develop profuse biofilms, ferment and assimilate dietary sugars, and produce collagenolytic proteinases are all indicative of their latent cariogenic potential. Based on the above, oral candidal counts have been used by some as a caries risk indicator. On the contrary, other studies suggest that Candida is merely a passenger extant in an acidic cariogenic milieu, and not a true pathogen. In this review, we critically examine the varying roles of Candida, and traditionally accepted cariogens such as the mutans group of streptococci in the pathobiology of dental caries. The weight of available data tends to imply that Candida may play a pivotal role as a secondary agent perpetuating the carious process, especially in dentinal caries.


Subject(s)
Biofilms , Candida albicans/metabolism , Carbohydrate Metabolism , Dental Caries/microbiology , Streptococcus mutans/metabolism , Acids/metabolism , Candida albicans/enzymology , Humans
5.
Expert Rev Anti Infect Ther ; 15(3): 299-318, 2017 03.
Article in English | MEDLINE | ID: mdl-27927053

ABSTRACT

INTRODUCTION: Candida species are common human commensals and cause either superficial or invasive opportunistic infections. The biofilm form of candida as opposed to its suspended, planktonic form, is predominantly associated with these infections. Alternative or adjunctive therapies are urgently needed to manage Candida infections as the currently available short arsenal of antifungal drugs has been compromised due to their systemic toxicity, cross-reactivity with other drugs, and above all, by the emergence of drug-resistant Candida species due to irrational drug use. Areas covered: Combination anti-Candida therapies, antifungal lock therapy, denture cleansers, and mouth rinses have all been proposed as alternatives for disrupting candidal biofilms on different substrates. Other suggested approaches for the management of candidiasis include the use of natural compounds, such as probiotics, plants extracts and oils, antifungal quorum sensing molecules, anti-Candida antibodies and vaccines, cytokine therapy, transfer of primed immune cells, photodynamic therapy, and nanoparticles. Expert commentary: The sparsity of currently available antifungals and the plethora of proposed anti-candidal therapies is a distinct indication of the urgent necessity to develop efficacious therapies for candidal infections. Alternative drug delivery approaches, such as probiotics, reviewed here is likely to be a reality in clinical settings in the not too distant future.


Subject(s)
Antifungal Agents/pharmacology , Candidiasis/prevention & control , Antifungal Agents/therapeutic use , Biofilms/drug effects , Candida/drug effects , Candida/immunology , Candida/physiology , Candidiasis/drug therapy , Candidiasis/therapy , Drug Delivery Systems , Humans , Immunotherapy , Photochemotherapy , Probiotics/therapeutic use , Quorum Sensing
6.
J Periodontal Res ; 52(3): 408-418, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27495271

ABSTRACT

BACKGROUND AND OBJECTIVE: Chronic periodontitis causes damage to tooth-supporting tissues, resulting in tooth loss in adults. Recently, cell-sheet-based approaches have been studied to overcome the limitations of conventional cytotherapeutic procedures for periodontal regeneration. The purpose of the present study was to investigate the regenerative potential of periodontal ligament stem cells (PDLSCs) and human umbilical vein endothelial cells (HUVECs) in three-dimensional (3D) cell sheet constructs for periodontal regeneration in vivo. MATERIAL AND METHODS: PDLSCs, HUVECs or co-cultures of both cells were seeded onto temperature-responsive culture dishes, and intact cell sheets were fabricated. Cell sheets were wrapped around the prepared human roots in three different combinations and implanted subcutaneously into immunodeficient mice. RESULTS: Histological evaluation revealed that after 2, 4 and 8 wk of implantation, periodontal ligament-like tissue arrangements were observed around the implanted roots in experimental groups compared with controls. Vascular lumens were also observed in periodontal compartments of HUVEC-containing groups. Periodontal ligament regeneration, cementogenesis and osteogenesis were evident in the experimental groups at both weeks 4 and 8, as shown by immunostaining for periostin and bone sialoprotein. Human cells in the transplanted cell sheets were stained by immunohistochemistry for the presence of human mitochondria. CONCLUSIONS: The 3D cell sheet-based approach may be potentially beneficial and is thus encouraged for future regenerative periodontal therapy.


Subject(s)
Guided Tissue Regeneration, Periodontal/methods , Human Umbilical Vein Endothelial Cells/cytology , Periodontal Ligament/cytology , Animals , Coculture Techniques/methods , Female , Human Umbilical Vein Endothelial Cells/physiology , Human Umbilical Vein Endothelial Cells/transplantation , Humans , Mice , Mice, SCID , Periodontal Ligament/physiology , Periodontal Ligament/transplantation , Tissue Scaffolds
7.
Braz. j. microbiol ; 47(4): 911-916, Oct.-Dec. 2016. tab
Article in English | LILACS | ID: biblio-828186

ABSTRACT

Abstract Objective Candida albicans is the primary causative agent of oral candidosis, and one of its key virulent attributes is considered to be its ability to produce extracellular phospholipases that facilitate cellular invasion. Oral candidosis can be treated with polyenes, and azoles, and the more recently introduced echinocandins. However, once administered, the intraoral concentration of these drugs tend to be sub-therapeutic and rather transient due to factors such as the diluent effect of saliva and cleansing effect of the oral musculature. Hence, intra-orally, the pathogenic yeasts may undergo a brief exposure to antifungal drugs. We, therefore, evaluated the phospholipase production of oral C. albicans isolates following brief exposure to sub-therapeutic concentrations of the foregoing antifungals. Materials and methods Fifty C. albicans oral isolates obtained from smokers, diabetics, asthmatics using steroid inhalers, partial denture wearers and healthy individuals were exposed to sub-therapeutic concentrations of nystatin, amphotericin B, caspofungin, ketoconazole and fluconazole for one hour. Thereafter the drugs were removed and the phospholipase production was determined by a plate assay using an egg yolk-agar medium. Results The phospholipase production of these isolates was significantly suppressed with a percentage reduction of 10.65, 12.14, 11.45 and 6.40% following exposure to nystatin, amphotericin B, caspofungin and ketoconazole, respectively. This suppression was not significant following exposure to fluconazole. Conclusions Despite the sub-therapeutic, intra oral, bioavailability of polyenes, echinocandins and ketoconazole, they are likely to produce a persistent antifungal effect by suppressing phospholipase production, which is a key virulent attribute of this common pathogenic yeast.


Subject(s)
Humans , Phospholipases/biosynthesis , Candida albicans/drug effects , Candida albicans/metabolism , Candidiasis, Oral/microbiology , Candidiasis, Oral/drug therapy , Antifungal Agents/pharmacology , Polyenes/therapeutic use , Polyenes/pharmacology , Azoles/therapeutic use , Azoles/pharmacology , Candida albicans/isolation & purification , Candida albicans/pathogenicity , Smoking , Microbial Sensitivity Tests , Dentures , Virulence Factors , Diabetes Mellitus , Enzyme Activation , Extracellular Space , Echinocandins/pharmacology , Antifungal Agents/therapeutic use
8.
Braz J Microbiol ; 47(4): 911-916, 2016.
Article in English | MEDLINE | ID: mdl-27522928

ABSTRACT

OBJECTIVE: Candida albicans is the primary causative agent of oral candidosis, and one of its key virulent attributes is considered to be its ability to produce extracellular phospholipases that facilitate cellular invasion. Oral candidosis can be treated with polyenes, and azoles, and the more recently introduced echinocandins. However, once administered, the intraoral concentration of these drugs tend to be sub-therapeutic and rather transient due to factors such as the diluent effect of saliva and cleansing effect of the oral musculature. Hence, intra-orally, the pathogenic yeasts may undergo a brief exposure to antifungal drugs. We, therefore, evaluated the phospholipase production of oral C. albicans isolates following brief exposure to sub-therapeutic concentrations of the foregoing antifungals. MATERIALS AND METHODS: Fifty C. albicans oral isolates obtained from smokers, diabetics, asthmatics using steroid inhalers, partial denture wearers and healthy individuals were exposed to sub-therapeutic concentrations of nystatin, amphotericin B, caspofungin, ketoconazole and fluconazole for one hour. Thereafter the drugs were removed and the phospholipase production was determined by a plate assay using an egg yolk-agar medium. RESULTS: The phospholipase production of these isolates was significantly suppressed with a percentage reduction of 10.65, 12.14, 11.45 and 6.40% following exposure to nystatin, amphotericin B, caspofungin and ketoconazole, respectively. This suppression was not significant following exposure to fluconazole. CONCLUSIONS: Despite the sub-therapeutic, intra oral, bioavailability of polyenes, echinocandins and ketoconazole, they are likely to produce a persistent antifungal effect by suppressing phospholipase production, which is a key virulent attribute of this common pathogenic yeast.


Subject(s)
Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/metabolism , Candidiasis, Oral/microbiology , Phospholipases/biosynthesis , Antifungal Agents/therapeutic use , Azoles/pharmacology , Azoles/therapeutic use , Candida albicans/isolation & purification , Candida albicans/pathogenicity , Candidiasis, Oral/drug therapy , Dentures , Diabetes Mellitus , Echinocandins/pharmacology , Enzyme Activation , Extracellular Space , Humans , Microbial Sensitivity Tests , Polyenes/pharmacology , Polyenes/therapeutic use , Smoking , Virulence Factors
9.
Oral Dis ; 22(3): 171-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26179810

ABSTRACT

Most viral infections encountered in resource-rich countries are relatively trivial and transient with perhaps fever, malaise, myalgia, rash (exanthema) and sometimes mucosal manifestations (enanthema), including oral in some. However, the apparent benignity may be illusory as some viral infections have unexpected consequences - such as the oncogenicity of some herpesviruses and human papillomaviruses. Infections are transmitted from various human or animal vectors, especially by close proximity, and the increasing movements of peoples across the globe, mean that infections hitherto confined largely to the tropics now appear worldwide. Global warming also increases the range of movement of vectors such as mosquitoes. Thus recent decades have seen a most dramatic change with the emergence globally also of new viral infections - notably human immunodeficiency viruses (HIV) - and the appearance of some other dangerous and sometimes lethal infections formerly seen mainly in, and reported from, resource-poor areas especially in parts of Asia, Latin America and Africa. This study offers a brief update of the most salient new aspects of the important viral infections, especially those with known orofacial manifestations or other implications for oral health care.


Subject(s)
Communicable Diseases, Emerging/complications , Communicable Diseases, Emerging/virology , DNA Virus Infections/complications , Facial Dermatoses/virology , Mouth Diseases/virology , RNA Virus Infections/complications , Chikungunya Fever/complications , Coronavirus Infections/complications , DNA Virus Infections/prevention & control , DNA Virus Infections/transmission , Dengue/complications , HIV Infections/complications , Hand, Foot and Mouth Disease/complications , Hemorrhagic Fever, Ebola/complications , Herpes Simplex/complications , Humans , Mumps/complications , Papillomavirus Infections/complications , Parvoviridae Infections/complications , RNA Virus Infections/prevention & control , RNA Virus Infections/transmission
11.
Mycopathologia ; 179(3-4): 195-204, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25515243

ABSTRACT

Candida albicans is a major agent of fungaemias and frequently causes systemic disease through seeded, blood stream dissemination. These infections, particularly common in hospitalized patients with central venous catheters (CVCs), appear to persevere due to biofilm reservoirs of the yeast that tend to develop on the device. Although it is known that candidal biofilms are intrinsically resistant to antifungals compared with their planktonic counterparts, there is a paucity of data on the expression of antifungal drug resistance genes (DRGs) in candidal biofilms in CVC reservoirs. Furthermore, notwithstanding the fact that CVCs are constantly bathed in human serum, there are no studies on the effect of the latter on the DRG expression in candidal biofilms. Hence, we developed in vitro biofilms of three different C. albicans strains on silicone CVC discs immersed in human serum and evaluated the temporal expression of nine antifungal DRGs. In an attempt to evaluate the effect of hyphal elements on DRG expression, we incorporated a hyphal mutant (HM) and its wild-type (WT) counterpart, as well as a fresh clinical isolate in the studies. Human serum significantly up-regulated DRG transcripts in Candida biofilms on CVCs, at different stages of biofilm growth, while the WT strain over-expressed more DRGs than the HM strain. Here, we report, for the first time, that both human serum and the hyphal elements of the yeast have a profound modulatory effect on DRG expression in C. albicans biofilms on CVCs.


Subject(s)
Biofilms/drug effects , Candida albicans/genetics , Central Venous Catheters/microbiology , Drug Resistance, Fungal , Serum/chemistry , Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/growth & development , Central Venous Catheters/adverse effects , Equipment Contamination , Fungal Proteins/genetics , Fungal Proteins/metabolism , Gene Expression Regulation, Fungal , Humans , Hyphae/drug effects , Hyphae/genetics , Hyphae/growth & development , Male , Up-Regulation
12.
Mycopathologia ; 178(3-4): 207-15, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25142726

ABSTRACT

Secretion of hydrolytic enzymes such as hemolysin is considered an important virulence attribute of the opportunistic pathogenic fungus Candida. It is known that Candida spp. isolated from HIV-infected patients produce copious hemolysins. As common antifungal agents may perturb the production of extracellular enzymes, we evaluated the effect of three antifungals nystatin, amphotericin B and fluconazole on the hemolytic activity of Candida albicans and Candida tropicalis isolates from HIV-infected individuals. The impact of antimycotics on hemolytic activity was assessed by a previously described in vitro plate assay, after exposing ten isolates each of C. albicans and C. tropicalis recovered from HIV-infected individuals to sub-minimum inhibitory concentrations (sub-MIC) of nystatin, amphotericin B and fluconazole. All Candida isolates showed a significant reduction in hemolytic activity. The reduction was highest for amphotericin B-exposed C. albicans and C. tropicalis followed by nystatin and fluconazole. The effect of antimycotics was more pronounced on the hemolytic activity of C. tropicalis compared to that of C. albicans. Commonly used antifungal agents significantly suppress hemolysin activity of Candida species. This implies that the antifungals, in addition to their lethality, may modulate key virulence attributes of the yeast. The clinical relevance of this phenomenon in HIV disease and other similar pathologies remains to be determined.


Subject(s)
Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/isolation & purification , Candida tropicalis/drug effects , Candida tropicalis/isolation & purification , Hemolysin Proteins/metabolism , Amphotericin B/pharmacology , Candida albicans/metabolism , Candida tropicalis/metabolism , Candidiasis, Oral/microbiology , Fluconazole/pharmacology , HIV Infections/complications , Hemolysin Proteins/antagonists & inhibitors , Humans , Microbiological Techniques , Nystatin/pharmacology , Virulence Factors/antagonists & inhibitors , Virulence Factors/metabolism
13.
J Investig Clin Dent ; 5(2): 81-90, 2014 May.
Article in English | MEDLINE | ID: mdl-24610628

ABSTRACT

Chronic periodontitis is a serious infectious and inflammatory oral disease of humans worldwide. Conventional treatment modalities are effective for controlling periodontal disease. However, the regeneration of damaged periodontal tissues remains a major challenge in clinical practice due to the complex structure of the periodontium. Stem cell-based regenerative approaches combined with the usage of emerging biomaterials are entering a new era in periodontal regeneration. The present review updates the current knowledge of periodontal ligament stem cell-based approaches for periodontal regeneration, and elaborates on the potentials for clinical application.


Subject(s)
Periodontal Ligament/cytology , Stem Cells/physiology , Biocompatible Materials/therapeutic use , Chronic Periodontitis/therapy , Guided Tissue Regeneration, Periodontal/methods , Humans , Multipotent Stem Cells/physiology , Tissue Scaffolds/chemistry
14.
APMIS ; 122(1): 47-58, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23656511

ABSTRACT

Mixed Candida-bacterial biofilms in urinary catheters are common in hospitalized patients. (i) The aims of this study were to evaluate, quantitatively and qualitatively, the in vitro development of mono- and dual-species biofilms (MSBs and DSBs) of Candida albicans and two enteric gram-negative bacilli (EGNB; Pseudomonas aeruginosa or Escherichia coli) on Foley catheter (FC) discs, (ii) to determine the biofilm growth in tryptic soy broth or glucose supplemented artificial urine (AU) and (iii) to assess the inhibitory effects of EGNB and their lipopolysaccharides (LPS) on Candida biofilm growth. The growth of MSBs and DSBs on FC discs was monitored by cell counts and SEM. The metabolic activity of LPS-treated Candida biofilms was determined by the XTT reduction assay. Candida albicans and EGNB demonstrated significant inter- and intra-species differences in biofilm growth on FC discs (p < 0.01). Pseudomonas aeruginosa suppressed Candida albicans significantly (p < 0.001) in DSBs. Compared with MSBs, DSB of EGNB in glucose supplemented AU demonstrated robust growth. Escherichia coli and its LPS, significantly suppressed Candida biofilm growth, compared with Pseudomonas aeruginosa and its LPS (p < 0.001). Candida albicans and EGNB colonization in FC is significantly increased in AU with glucose, and variably modified by Escherichia coli, Pseudomonas aeruginosa and their corresponding LPS.


Subject(s)
Biofilms/growth & development , Candida/physiology , Candida/pathogenicity , Catheter-Related Infections/microbiology , Catheter-Related Infections/prevention & control , Escherichia coli/physiology , Pseudomonas aeruginosa/physiology , Urinary Catheters/adverse effects , Urinary Catheters/microbiology , Biofilms/drug effects , Catheter-Related Infections/etiology , Cell Adhesion/drug effects , Culture Media , Dietary Carbohydrates/pharmacology , Escherichia coli/growth & development , Humans , Lipopolysaccharides/pharmacology , Microscopy, Electron, Scanning , Pseudomonas aeruginosa/growth & development
15.
J Periodontal Res ; 49(3): 299-306, 2014 Jun.
Article in English | MEDLINE | ID: mdl-23738684

ABSTRACT

BACKGROUND AND OBJECTIVE: To investigate the expression of osteo/odontogenic differentiation markers and vascular network formation in a 3D cell sheet with varying cell ratios of periodontal ligament stem cells (PDLSCs) and human umbilical vein endothelial cells (HUVECs). MATERIAL AND METHODS: Human PDLSCs were isolated and characterized by flow cytometry, and co-cultured with HUVECs for the construction of cell sheets. Both types of cells were seeded on temperature-responsive culture dishes with PDLSCs alone, HUVECs alone and various ratios of the latter cells (1 : 1, 2 : 1, 5 : 1 and 1 : 5) to obtain confluent cell sheets. The expressions of osteo/odontogenic pathway markers, including alkaline phosphatase (ALP), bone sialoprotein (BSP) and runt-related transcription factor 2 (RUNX2), were analyzed at 3 and 7 d using RT-PCR. Further ALP protein quantification was performed at 7 and 14 d using ALP assay. The calcium nodule formation was assessed qualitatively and quantitatively by alizarin red assay. Histological evaluations of three cell sheet constructs treated with different combinations (PDLSC-PDLSC-PDLSC/PDLSC-HUVEC-PDLSC/co-culture-co-culture-co-culture) were performed with hematoxylin and eosin and immunofluorescence staining. Statistical analysis was performed using t-test (p < 0.05). RESULTS: Significantly higher ALP gene expression was observed at 3 d in 1 : 1 (PDLSC-HUVEC) (2.52 ± 0.67) and 5 : 1 (4.05 ± 1.07) co-culture groups compared with other groups (p < 0.05); this was consistent with ALP protein quantification. However, the expression of BSP and RUNX2 genes was higher at 7 d compared to 3 d. Significant calcium mineralization was detected as quantified by alizarin red assay at 14 d in 1 : 1 (1323.55 ± 6.54 µm) and 5 : 1 (994.67 ± 4.15 µm) co-cultures as compared with monoculture cell sheets (p < 0.05). Hematoxylin and eosin and CD31 immunostaining clearly exemplified the development of a layered cell sheet structure with endothelial cell islands within the constructed PDLSC-HUVEC-PDLSC and co-culture groups. Furthermore, HUVECs invaded the layered cell sheet, suggestive of rudimentary vascular network initiation. CONCLUSION: This study suggests that the PDLSC-HUVEC co-culture, cell sheet, model exhibits significantly high levels of osteo/odontogenic markers with signs of initial vascular formation. This novel 3D cell sheet-based approach may be potentially beneficial for periodontal regenerative therapy.


Subject(s)
Human Umbilical Vein Endothelial Cells/physiology , Odontogenesis/physiology , Osteogenesis/physiology , Periodontal Ligament/cytology , Stem Cells/physiology , Alkaline Phosphatase/analysis , Anthraquinones , Biomarkers/analysis , Calcification, Physiologic/physiology , Cell Culture Techniques , Cell Differentiation/physiology , Cell Survival/physiology , Cells, Cultured , Coculture Techniques , Coloring Agents , Core Binding Factor Alpha 1 Subunit/analysis , Humans , Integrin-Binding Sialoprotein/analysis , Real-Time Polymerase Chain Reaction/methods , Time Factors , Tissue Engineering/instrumentation
16.
Arch Oral Biol ; 58(10): 1327-34, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23880095

ABSTRACT

OBJECTIVE: Enterococcus faecalis is a bacterial pathogen that is often associated with endodontic infections. Biofilm formation is a key virulence attribute in the pathogenicity of E. faecalis. In the present study, we comprehensively examined the effect of various culture media and nutrients on the development of E. faecalis biofilms. DESIGN: A reference strain and a clinical isolate of E. faecalis were used in all experiments for comparison. Commonly used liquid culture media with different nutrient compositions were used to support the development of E. faecalis biofilms in a time-dependent assay. E. faecalis biofilms were quantified by colony forming unit (CFU) and crystal violet (CV) assays. Biofilm architecture and cellular viability were evaluated by scanning electron microscopy and confocal laser scanning microscopy. RESULTS: Growth kinetics evaluated by CFU and CV assays and by microscopy showed that E. faecalis biofilms reached maturity at 72h. "Pg broth" (Tryptic Soy Broth with yeast extract, hemen and vitamin K) promoted E. faecalis biofilm formation more than Brain Heart Infusion broth or Tryptic Soy Broth. Addition of 2% glucose enhanced biofilm formation. Thus, it seems that nutrients such as hemen, vitamin K and glucose are important for E. faecalis for the formation of biofilms. CONCLUSION: The present study demonstrated that nutrient-rich media containing glucose enhances the formation of E. faecalis biofilms, which exhibit maturation at 72h.


Subject(s)
Biofilms/drug effects , Biofilms/growth & development , Culture Media/pharmacology , Enterococcus faecalis/drug effects , Enterococcus faecalis/growth & development , Enterococcus faecalis/pathogenicity , Enterococcus faecalis/ultrastructure , Humans , Microscopy, Confocal , Microscopy, Electron, Scanning , Virulence
17.
J Med Microbiol ; 62(Pt 2): 303-318, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23002065

ABSTRACT

Virulence associated with fluconazole (FL) resistance in Candida glabrata is a global problem and has not been well characterized at the proteome level. In this study, a stable FL-resistant (MIC >256 µg ml(-1)) strain of C. glabrata was generated on agar containing FL. Eight phenotypic mutants were characterized by contour-clamped homogeneous electrophoretic field analysis and two-dimensional PAGE. The secondary derivatives of C. glabrata yielded four distinct genotypes with varying chromosomal profiles. Proteomic analysis performed by tandem mass spectrometry for two of the mutants, CG(L2) and CG(S3), demonstrated a total of 25 differentially regulated proteins of which 13 were upregulated and 12 were downregulated or were similar compared with the parental isolate. The mRNA transcript levels of significantly (P<0.001) upregulated genes were determined by quantitative RT-PCR analysis, and their physiological relevance in terms of phenotypic expression of virulence attributes was verified by conventional laboratory methodologies. The data showed that the FL resistance (MIC >256 µg ml(-1)) of CG(S3) was associated with significantly upregulated (P<0.001) mRNA transcript levels of several genes - ERG11, CDR1, CDR2, MFS, MTI, TPR, VPS and EFT2 - in addition to a number of other potentially virulent genes expressed differentially at a lower level. The results demonstrated accentuated phenotypic expression of bud formation of yeast and metallothionein production associated with FL resistance in C. glabrata, which may help the fungus to colonize the host.


Subject(s)
Candida glabrata/drug effects , Drug Resistance, Fungal/genetics , Fluconazole/pharmacology , Fungal Proteins/biosynthesis , Metallothionein/biosynthesis , Antifungal Agents/pharmacology , Candida glabrata/genetics , Candida glabrata/pathogenicity , Candidiasis/drug therapy , Candidiasis/microbiology , DNA, Fungal/genetics , Fluconazole/metabolism , Fungal Proteins/genetics , Gene Expression Regulation, Fungal , Genes, Fungal , Microbial Sensitivity Tests , Molecular Typing , Proteomics , RNA, Messenger/biosynthesis , Virulence Factors/biosynthesis , Virulence Factors/genetics
18.
Mol Oral Microbiol ; 28(1): 54-69, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23194472

ABSTRACT

Elucidation of bacterial and fungal interactions in multispecies biofilms will have major impacts on understanding the pathophysiology of infections. The objectives of this study were to (i) evaluate the effect of Pseudomonas aeruginosa lipopolysaccharide (LPS) on Candida albicans hyphal development and transcriptional regulation, (ii) investigate protein expression during biofilm formation, and (iii) propose likely molecular mechanisms for these interactions. The effect of LPS on C. albicans biofilms was assessed by XTT-reduction and growth curve assays, light microscopy, scanning electron microscopy (SEM), and confocal laser scanning microscopy (CLSM). Changes in candidal hypha-specific genes (HSGs) and transcription factor EFG1 expression were assessed by real-time polymerase chain reaction and two-dimensional gel electrophoresis, respectively. Proteome changes were examined by mass spectrometry. Both metabolic activities and growth rates of LPS-treated C. albicans biofilms were significantly lower (P < 0.05). There were higher proportions of budding yeasts in test biofilms compared with the controls. SEM and CLSM further confirmed these data. Significantly upregulated HSGs (at 48 h) and EFG1 (up to 48 h) were noted in the test biofilms (P < 0.05) but cAMP levels remained unaffected. Proteomic analysis showed suppression of candidal septicolysin-like protein, potential reductase-flavodoxin fragment, serine hydroxymethyltransferase, hypothetical proteins Cao19.10301(ATP7), CaO19.4716(GDH1), CaO19.11135(PGK1), CaO19.9877(HNT1) by P. aeruginosa LPS. Our data imply that bacterial LPS inhibit C. albicans biofilm formation and hyphal development. The P. aeruginosa LPS likely target glycolysis-associated mechanisms during candidal filamentation.


Subject(s)
Biofilms/growth & development , Candida albicans/drug effects , Hyphae/drug effects , Lipopolysaccharides/pharmacology , Pseudomonas aeruginosa/physiology , Adenosine Triphosphatases/drug effects , Candida albicans/genetics , Candida albicans/physiology , Cyclic AMP/analysis , DNA-Binding Proteins/drug effects , Fungal Proteins/drug effects , Fungal Proteins/genetics , Gene Expression Regulation, Fungal/drug effects , Glycine Hydroxymethyltransferase/drug effects , Glycolysis/drug effects , Humans , Hydrolases/drug effects , Hyphae/genetics , Klebsiella pneumoniae/physiology , Membrane Glycoproteins/drug effects , Microbial Interactions , NADH, NADPH Oxidoreductases/drug effects , Phosphoglycerate Kinase/drug effects , Proteome/genetics , Sugar Alcohol Dehydrogenases/drug effects , Transcription Factors/drug effects , Transcription, Genetic/drug effects
19.
J Hosp Infect ; 81(2): 79-86, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22595316

ABSTRACT

BACKGROUND: Most clinical guidelines for the use of biocides have been developed for planktonic micro-organisms, but in nature, most micro-organisms live as surface-adherent communities or biofilms. AIM: To evaluate the effectiveness of commonly used biocides against Escherichia coli and Candida spp. in three distinct growth phases: planktonic, adhesion and biofilm. METHODS: Ultrastructural, architectural and cellular viability changes following a 5 min exposure to biocide were monitored by scanning electron microscopy and confocal laser scanning microscopy using fluorescent dyes. Comparative transcript expression of the antioxidants SOD1 and CAT1 in the planktonic and biofilm phases was evaluated using quantitative real-time polymerase chain reaction. FINDINGS: E. coli and Candida spp. in the planktonic phase were susceptible to all the tested biocides at the recommended concentrations. However, early adhesion and late biofilm phases of both were less susceptible to the biocides, and exceeded the recommended concentrations on several occasions. A short period of biocide exposure failed to fully eradicate the adherent microbial cells, and they recovered from the biocide challenge, forming biofilm on the biocide-treated surfaces. The biofilm phase showed higher expression of SOD1 and CAT1. CONCLUSION: The recommended concentrations of biocides for clinical disinfection in the hospital setting may not fully eradicate the adhesion or biofilm phases of E. coli and Candida spp. Higher antioxidative capacities in microbial biofilms may be responsible for the resistance of biofilms against clinical biocides.


Subject(s)
Biofilms/drug effects , Candida/physiology , Disinfectants/pharmacology , Drug Resistance, Bacterial , Drug Resistance, Fungal , Escherichia coli/physiology , Candida/drug effects , Candida/ultrastructure , Catalase/biosynthesis , Escherichia coli/drug effects , Escherichia coli/ultrastructure , Gene Expression Profiling , Humans , Microbial Sensitivity Tests , Microbial Viability/drug effects , Microscopy, Confocal , Microscopy, Electron, Scanning , Oxidative Stress , Stress, Physiological , Superoxide Dismutase/biosynthesis , Superoxide Dismutase-1
20.
Oral Dis ; 18(3): 244-54, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22126675

ABSTRACT

The oral cavity serves as a reservoir of Staphylococcus aureus for infection of the lower respiratory tract and cross-infection to other patients. This systematic review was designed to examine the effectiveness of oral health promotion interventions on this pathogen. The PubMed, ISI Web of Science, and Cochrane Library databases were searched for clinical trials assessing the effect of oral health promotion interventions on oral and oropharyngeal carriage of S. aureus. Oral health promotion interventions on oral reservoirs of S. aureus in both systemically healthy and medically compromised groups consisted of oral hygiene interventions only. There was a lack of evidence pertaining to the effectiveness of mechanical oral hygiene interventions against this pathogen. Chlorhexidine delivered in oral hygiene products such as mouthrinses, gels, and sprays appeared to have some utility against S. aureus, although some studies found equivocal effects. There was a dearth of studies investigating the efficacy of other chemical agents. Although many chemical agents contained in oral hygiene products have proven in vitro activity against S. aureus, their clinical effectiveness and potential role as adjuncts or alternative therapies to conventional treatment remain to be confirmed by further high-quality randomized controlled trials.


Subject(s)
Health Promotion , Mouth/microbiology , Oral Health , Staphylococcus aureus/isolation & purification , Anti-Infective Agents, Local/therapeutic use , Humans , Oral Hygiene/methods , Oropharynx/microbiology , Staphylococcal Infections/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...